色妺妺免费影院,www.三级.com,一区二区福利视频

BMS Full Year 2025 Financial Report BMS Bristol Myers Squibb reports 2025 results with stable revenue, a sharp rebound in profitability, strong growth from new products, and resilient Eliquis sales reaching $14.4 billion despite patent pressures.
Global Biopharma Layoffs February 2026 Layoffs Global Biopharma companies including GSK, IO Biotech, and Bitterroot Bio announce workforce reductions in February 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Global Biopharma Layoffs July 2025 Layoffs Biopharmaceutical industry sees major July layoffs, with companies like Sarepta, GSK, Century, and Sage Therapeutics cutting jobs amid restructurings, trial setbacks, and M&A activity.
Cigna Files Antitrust Suit Over Pomalyst Monopoly BMS Cigna has filed a major antitrust lawsuit against Bristol Myers Squibb, accusing the company of anti-competitive tactics to delay generic competition for the blockbuster drug Pomalyst, costing payers billions.
Bristol Myers Defends Cobenfy Amid Setbacks BMS Bristol Myers defends its antipsychotic drug Cobenfy despite a failed phase 3 trial and slowing prescriptions. The company remains optimistic, citing physician support and ongoing trials in Alzheimer’s, bipolar disorder, and autism.
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal BMS Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
ASCO 2025: BMS Defends Opdualag's Future After Adjuvant Melanoma Setback BMS Bristol Myers Squibb’s Opdualag failed to improve outcomes in adjuvant melanoma, raising questions about LAG-3 antibodies. Despite this, BMS remains confident in ongoing NSCLC trials targeting PD-1 positive patients.
Bristol Myers Joins BioNTech in $11B Bispecific Pact BMS Bristol Myers Squibb partners with BioNTech in an $11B deal to co-develop the PD-L1xVEGF-A bispecific BNT327, strengthening its immuno-oncology portfolio amid rising competition from Merck and Pfizer.
BMS's Q1 2025 Financial report Market Trend Bristol Myers Squibb Q1 2025 earnings: revenue down 6% YoY, but strong product performance drives EPS growth. Full-year guidance raised. Highlights include Opdivo, Reblozyl, and Breyanzi.
BMS Schizophrenia Adjunct Therapy Cobenfy Phase III Trial Results Fail BMS Bristol Myers Squibb's Phase III ARISE trial of Cobenfy as adjunctive therapy for schizophrenia did not meet its primary endpoint but showed encouraging trends and a consistent safety profile.

<Pre12 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a